A life sciences hedge fund has gone activist on one of its smaller holdings.
Soleus Capital Management converted its 13G filing, which suggests a passive investment, to a 13D document for Montreal-based Theratechnologies, a biopharmaceuticals company focused on the development and commercialization of innovative therapies.
